ALBUMEX® 4 (Human Albumin 4% [40g/L]) is being replaced with ALBUREX® 5 AU (Human Albumin 5% [50g/L]) from September 2023¹

Please note that ALBUMEX® 4 and ALBUREX® 5 AU are different products. Once your supplies of ALBUMEX® 4 are exhausted, you will notice that your hospital blood bank will supply you with ALBUREX® 5 AU and ALBUMEX® 4 will no longer be available for your patients.

What you need to know

1.	Both products are manufactured using domestically sourced Australian plasma but are NOT interchangeable due to a difference in concentration ^{2,3}		
2.	The concentration is different		
	a. ALBUMEX [®] 4 contains Human Albumin 4% (40g/L) ²	b. ALBUREX® 5 AU contains Human Albumin 5% (50g/L) ³	
3.	Available vial sizes are different		
	 a. ALBUMEX® 4 is available in two sizes: a 50mL vial (containing 2g Human Albumin)² a 500mL vial (containing 20g Human Albumin)² 	 b. ALBUREX® 5 AU will be available in two sizes: a 250mL vial (containing 12.5g of Human Albumin)³ a 500mL vial (containing 25g of Human Albumin)³ 	
4.	The colour of the vials can vary. Human albumin can appear clear but slightly viscous liquid, almost colourless, yellow, amber, or green ⁴		
	ALBUMEX® 4	ALBUREX® 5 AU	
	State of the state	Affairs on T S All Annual and the property of	

Information on how to calculate the correct dose^{2,3}

Please find below a table to help you calculate the correct volume of Human Albumin 5%.

Calculation: Human Albumin (g) / 0.05 = volume (mL) required of ALBUREX® 5 AU

For example: 10g of Human Albumin / 0.05 = 200mL of ALBUREX® 5 AU required

Amount of Human Albumin required	Volume of ALBUMEX® 4 (Human Albumin 4%) (to be discontinued)	Volume of ALBUREX® 5 AU (Human Albumin 5%) (new product)
2g	50mL	40mL
5g	125mL	100mL
10g	250mL	200mL
12.5g	312.5mL	250mL*
20g	500mL	400mL
25 g	625mL	500mL*

^{*}Available vial size.

CSL Behring

IMPORTANT INFORMATION FOR HEALTHCARE PROFESSIONALS

What actions do you need to take?

Please ensure you review the correct prescribing information (see below) and check all records and prescriptions carefully before dispensing and infusing the product.

You should adhere to your hospital policy regarding safe and accurate product administration and carefully read the product label to verify the strength of the product prior to drawing up and infusing.

What to do if you suspect a patient has been incorrectly infused

If you suspect a patient has been administered the incorrect product or dose/volume, please follow your normal processes for investigating and reporting.

This includes reporting the suspected event as soon as it occurs (preferably within 1 working day) to:

- · medicalinformation@cslbehring.com.au OR
- Directly to the Therapeutic Goods Administration via their Adverse Event Management System at https://aems.tga.gov.au

Information needed to report a suspected adverse event includes:

- Details about the event (including the date it occurred)
- · Patient identifiers such as initials, date of birth, and gender
- · Information on the product involved (including the batch number)

Contact Information

For CSL Behring Medical Information Enquiries:

Please telephone 1800 642 865 or email medicalinformation@cslbehring.com.au

For BloodNet and General enquiries about the transition:

Please call the National Blood Authority on 13 000 BLOOD (13 000 25663) or email supply.management.plasma@blood.gov.au

ALBUMEX® 4 and ALBUREX® 5 AU are funded under arrangements implemented by the National Blood Authority. Please refer to the National Blood Authority for details.



Scan the QR code to find out more about this transition, or please visit hcp.cslbehring.com.au/

Before prescribing, please review the Product Information available by scanning the QR codes.

ALBUMEX® 4



ALBUREX® 5 AU



References: 1. National Blood Authority. Transition of Australia's domestic plasma products. Available at: https://www.blood.gov.au/Transition%20of%20Australia%E2%80%99s%20Domestic%20Plasma%20Products. Accessed: 17 August 2023. **2.** ALBUMEX® 4 Approved Product Information. **3.** ALBUREX® 5 AU Approved Product Information. **4.** McCann K, et al. Biologicals. 2009;37:32–36.

ALBUREX® is a registered trade mark of CSL Group of Companies. For information: CSL Behring (Australia) Pty Ltd: For Customer Service Enquiries: Phone 1800 063 892. E-mail: customerservice@cslbehring.com.au. Internet: www.cslbehring.com.au. CSL Behring (Australia) Pty Ltd. 655 Elizabeth Street, Melbourne, Victoria, Australia, 3000. ABN: 48 160 734 761. CSB8027. August 2023. AU-AAU-0006.

CSL Behring